- Celtrix' SomatoKine (IGF-BP3 complex) is safe and delivers insulin-like growth factor-1 at higher dose levels than has ever been feasible before, according to the results of the firm's first Phase I study. IGF-1 is the active ingredient in Cephalon's Myotrophin (somatomedin C), which is nearing the market for the treatment of amyotrophic lateral sclerosis. Celtrix hopes to develop the drug, which is formulated along with its binding protein, for conditions such as major surgery, organ damage/failure after trauma, and severe osteoporosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze